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1. Introduction
Metabolic syndrome (MetS) consists of a combination of
metabolic disorders, including increased abdominal circum-
ference, hyperglycemia, elevated blood pressure, and lipid
disorders. MetS is now widely accepted as a crucial risk
factor for the development of cardiovascular disease (CVD)
and mortality. In addition, persistent proteinuria indicating
chronic kidney disease (CKD) is well known as a powerful
risk factor for the progression of end-stage renal disease and
CVD. In recent years, patients with CKD and MetS appear
to be increasing along with increasing incidence of CVD in
industrial countries.
In order to ameliorate cardiovascular mortality, it is
essential to extend comprehensive treatments for patients
with CKD and MetS. Although those disorders may be partly
formed by a certain common pathological basis, there is
insuﬃcient knowledge of the underlying interplay between
the pathological conditions and CVD. For this special issue,
we asked front-line researchers and authors to submit origi-
nal research and review articles on the interactions between
CKD and MetS and the development of CVD. Finally, we
were able to publish 10 review articles and 4 original research
articles that provide pivotal evidence for understanding the
pathophysiological relationships among the disorders on a
clinical basis and a molecular basis. The following articles
will serve very useful treatment strategies for promoting
worldwide public health.
2. Review Articles
K. Nitta reviewed the epidemiology of MetS and CKD and
focused on the possible linkage between CKD and MetS
leading to an increase in cardiovascular events. The author
described a fundamental treatment strategy including life-
style modification and renal protection by renin-angiotensin
blockade and/or statins.
D. Vykoukal and M. G. Davies showed influences of MetS
on the hemostatic disorders and development of CKD and
the outcomes of percutaneous renal intervention in patients
with symptomatic atherosclerotic renal and fibromuscular
dysplasia renal artery disease.
Y.-J. Sheen and W. H.-H. Sheu summarized the relation
between MetS and CKD from epidemiological, biological,
and clinical aspects. They clearly revealed the significance of
several biomarkers and the importance of MetS as a ther-
apeutic target for preventing CKD.
Since much attention has been paid to the role of oxida-
tive stress in promoting not only the severity of CVD but
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also the progression of CKD, E. O. Gosmanova and N.-A.
Le focused on the central roles of oxidative stress in the
development of CVD and its complications in patients with
CKD.
M. Raimundo and J. A. Lopes reviewed in detail the
associations between and treatment strategies for CKD,
MetS, and CVD. They clearly described clinical evidence and
pathophysiology, including insulin resistance, inflammation,
endothelial dysfunction, oxidative stress, renal circulation,
renin-angiotensin-aldosterone system and sympathetic ner-
vous system, and dietary factors.
Y. Beyazit et al. demonstrated the eﬀect of bone marrow
angiotensin II signaling on the initiation and progression of
atherosclerosis with inflammation and oxidative stress in-
volving endothelial cells and hematopoietic cells.
M. Mogi and M. Horiuchi showed the cerebrorenal con-
nection mainly from a clinical point of view. They demon-
strated that cerebral and glomerular small vessel diseases are
based on a common pathogenesis through anatomic and
vasoregulatory similarities. These issues indicate that CKD
markers may be helpful for predicting the future risk of
neuronal diseases such as stroke, dementia, and cognitive
impairment.
K. Aihara et al. focused on the interplay between the
TGF-β1 signaling pathway and the development of CVD,
CKD, and MetS. Understanding the TGF-β1 signaling path-
way and appropriate modulation of the biological actions of
TGF-β1 is a valuable therapeutic approach to reduce CVD.
Y. Okamoto reviewed the clinical significance of hypoad-
iponectinemia in cardiovascular diseases and the protective
features of adiponectin against cardiovascular remodeling,
including cardiac hypertrophy, hypertension, atherosclerosis,
and pulmonary artery hypertension.
M. Tesauro et al. showed that adipose tissue secretes bio-
active adipokines, including adiponectin, leptin, adipsin,
and visfatin, into the whole body circulation. Accumulating
evidence about these factors would serve a strategy for pro-
tection of both renal and cardiovascular systems.
3. Original Research Articles
Since height is inversely associated with augmentation index
indicating arterial stiﬀness, T. Takenaka et al. showed that not
only cigarette smoking but also short height independently
contributes to total mortality in hemodialysis patients.
V. B. Djordjevic´ et al. showed that available biomarkers
in patients with coronary artery disease with and without
statin treatment are C-reactive protein in acute myocardial
infarction, triglyceride/apoB in stable angina pectoris, and
lipoprotein (a) in unstable angina pectoris.
V. S. Rao et al. showed that among the biological cardio-
vascular risk markers, oxidized LDL cholesterol is the most
powerful predictor of the incidence of MetS in 2316
individuals who were recruited in Phase I of the Indian
Atherosclerosis Research Study (IARS).
C. S. Coﬀey et al. showed that subjects with MetS have
higher levels of PAI-1 and t-PA antigen than do subjects
without MetS in a population study. Since these factors have
been known to increase the risk of cardiovascular disease,
they raised the possibility that an accelerated coagulation
state is linked with the pathological basis of MetS.
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